Revenue: As of FY2025 Q3, the actual value is USD 60.17 M.EPS: As of FY2025 Q3, the actual value is USD -0.1.EBIT: As of FY2025 Q3, the actual value is USD -1.707 M.<h3>Telehealth Segment</h3><ul><li>Revenue, net: Increased to $47,279,933 for the three months ended September 30, 2025, from $40,154,683 in 2024. For the nine months ended September 30, 2025, revenue was $147,186,714, up from $109,687,054 in 2024.</li><li>Cost of Revenue: Rose to $6,714,235 for the three months ended September 30, 2025, from $4,300,877 in 2024. For the nine months ended September 30, 2025, it was $21,689,400, compared to $13,049,315 in 2024.</li><li>Segment Operating Loss: Improved to - $3,043,374 for the three months ended September 30, 2025, from - $3,745,522 in 2024. For the nine months ended September 30, 2025, the loss was - $6,571,978, compared to - $15,557,309 in 2024.</li></ul><h3>WorkSimpli Segment</h3><ul><li>Revenue, net: Slightly decreased to $12,892,537 for the three months ended September 30, 2025, from $13,117,611 in 2024. For the nine months ended September 30, 2025, revenue was $39,788,325, up from $39,650,009 in 2024.</li><li>Cost of Revenue: Decreased to $693,678 for the three months ended September 30, 2025, from $712,664 in 2024. For the nine months ended September 30, 2025, it was $1,793,133, compared to $1,589,318 in 2024.</li><li>Segment Operating Income (Loss): Improved to $1,074,160 for the three months ended September 30, 2025, from - $250,752 in 2024. For the nine months ended September 30, 2025, income was $5,125,544, compared to $1,124,261 in 2024.</li></ul><h3>Consolidated</h3><ul><li>Total Revenue, net: Increased to $60,172,470 for the three months ended September 30, 2025, from $53,272,294 in 2024. For the nine months ended September 30, 2025, revenue was $186,975,039, up from $149,337,063 in 2024.</li><li>Operating Loss: Improved to - $1,969,214 for the three months ended September 30, 2025, from - $3,996,274 in 2024. For the nine months ended September 30, 2025, the loss was - $1,446,434, compared to - $14,433,048 in 2024.</li><li>Net Loss: Improved to - $3,387,521 for the three months ended September 30, 2025, from - $4,554,871 in 2024. For the nine months ended September 30, 2025, the loss was - $4,154,043, compared to - $16,000,791 in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Provided by Operating Activities: $11,560,698 for the nine months ended September 30, 2025, compared to $16,439,889 in 2024.</li><li>Net Cash Used in Investing Activities: - $10,161,401 for the nine months ended September 30, 2025, compared to - $8,815,591 in 2024.</li><li>Net Cash Used in Financing Activities: - $12,618,450 for the nine months ended September 30, 2025, compared to - $3,183,770 in 2024.</li></ul><h3>Future Outlook</h3>The company expects its existing cash of $23.8 million as of September 30, 2025, to be sufficient to fund planned operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of these unaudited condensed consolidated financial statements.

LifeMD Pref Share LFMDP 8.875 Perp 10/15/22 | 10-Q: FY2025 Q3 Revenue: USD 60.17 M